ResMed Inc. 10-Q Summary: Quarter Ended March 31, 2006
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a developer, manufacturer, and marketer of medical equipment for the diagnosis and treatment of sleep-disordered breathing. The report covers the three and nine-month periods ended March 31, 2006. All share and per-share data have been retroactively adjusted to reflect a two-for-one stock split distributed on September 30, 2005.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2006 | Nine Months Ended Mar 31, 2006 |
|---|---|---|
| Net Revenue | $162.3 million | $435.8 million |
| Gross Profit | $100.9 million | $272.7 million |
| Gross Margin | 62.1% | 62.6% |
| Net Income | $26.4 million | $65.1 million |
| Diluted EPS | $0.34 | $0.87 |
| Cash from Operations (9mo) | $63.7 million | |
| Total Debt (Current + Long-term) | $96.5 million | |
| Cash & Equivalents | $166.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 50% year-over-year for the quarter (from $108.5M to $162.3M) and 45% for the nine-month period. Growth was driven by increased unit sales of flow generators and masks, as well as $15.5 million in incremental revenue from recent acquisitions (PolarMed, Pulmomed, Saime, Hoefner, Resprecare).
- Profitability: Net income rose 48% for the quarter and 32% for the nine-month period. Diluted EPS increased from $0.25 to $0.34 for the quarter.
- Margin Compression: Gross margin decreased from 65% to 62% for the quarter. Management attributes this to a shift in geographic mix (higher domestic sales) and product mix (higher percentage of lower-margin flow generator sales relative to masks).
- Debt Restructuring: The company converted all $113.25 million of its 4% Convertible Subordinated Notes into common stock during the quarter, eliminating associated interest expense. Concurrently, the company drew $35 million on a new $75 million revolving credit facility.
- Stock-Based Compensation: The adoption of SFAS 123(R) resulted in $3.7 million of stock-based compensation expense for the quarter and $11.4 million for the nine-month period, reducing net income compared to prior year reporting standards.
Guidance, Outlook, and Risks
- Expense Outlook: Management expects Selling, General, and Administrative (SG&A) expenses to be 33% to 35% of net revenue for fiscal year 2006. Research and Development (R&D) expenses are expected to be 5% to 7% of net revenue.
- Capital Expenditures: Significant capital spending ($79.1M for the nine months) is ongoing for a new R&D/administration facility in Sydney (completion expected late 2006) and a new corporate headquarters in San Diego (construction expected to begin in 2006).
- Acquisition Integration: The company is integrating recent acquisitions (PolarMed, Pulmomed) and restructuring German operations (ResMed Germany and MAP) to achieve cost efficiencies.
- Risks: Key risks include foreign currency fluctuations (hedged via options), reliance on third-party reimbursement rates, regulatory compliance (FDA), and the successful integration of acquired entities. The company faces potential tax audit adjustments in Germany and patent litigation risks.
Investor Verification Checklist
- Acquisition Synergies: Verify the realization of revenue and cost synergies from the PolarMed and Pulmomed acquisitions.
- Margin Trends: Monitor whether the shift toward flow generator sales continues to pressure gross margins or if product mix stabilizes.
- Debt Covenants: Confirm continued compliance with financial covenants on the new $75M revolving facility and the EUR 50M syndicated loan.
- Capital Project Costs: Track actual vs. estimated costs for the Sydney and San Diego construction projects to ensure no overruns impact liquidity.
- Stock-Based Compensation Impact: Assess the ongoing impact of SFAS 123(R) on future earnings per share as unvested options are recognized.